Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b, First-in-human, Multicenter Study to Assess the Efficacy and Safety of RGT-61159 for Treatment of Patients With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

NCT06462183 is registered in ClinicalTrials.gov with Rgenta Therapeutics Inc as lead sponsor.

NCT NCT06462183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06462183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b, First-in-human, Multicenter Study to Assess the Efficacy and Safety of RGT-61159 for Treatment of Patients With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
Lead sponsor
Rgenta Therapeutics Inc
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 19, 2024
Completion date
December 31, 2027
Enrollment
105 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma, colorectal cancer